When it comes to relapsed/refractory follicular lymphoma, chimeric antigen receptor (CAR) T-cell therapy has become a go-to ...

Long-term results from a randomized trial confirmed that early rituximab monotherapy for advanced-stage, asymptomatic, low ...

remains a useful treatment strategy, although the optimal timing of such approaches requires further clarification. Follicular lymphoma is a very diverse disease, and decisions to treat in the ...

Michael Wolff was at the "edge of a cliff" when he was diagnosed with a cancer that affects less than 300 patients a year in the U.S.

Long-term results of a phase 3 trial show that early rituximab monotherapy significantly delays the need for new treatment in ...

questioning why my lymphoma responded to therapy while others did not. When I started receiving treatment for follicular lymphoma, I wasn’t sure what to expect regarding treatment — and a lot of ...

These patients have limited treatment options and poor prognoses ... including 8 with diffuse large B-cell lymphoma, 2 with transformed follicular lymphoma, 1 with high-grade B-cell lymphoma ...

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

Cheyney, PA, May, 5 2025 - Navrogen, Inc., a biopharmaceutical company specialized in developing antibody-based therapies for ...